The reasons for its absence from the US market are multifactorial: No FDA Application Filed: Ever Neuro Pharma, the Austrian manufacturer, has not pursued FDA approval
The dose depends on whats in it
doi: 10.1029/2021GL094143, 74 MerinoN.AronsonH
For example, the final geometric mean cost listed in Addendum J for the code combination described by complexity adjustment assignment 3320R, which is assigned to C-APC 5224 (Level 4 Pacemaker and Similar Procedures), includes all paired code combinations that will be reassigned to C-APC 5224 when CPT code 33208 is the primary code
Continuous training for all Strive compounding staff to demonstrate full competency and cultivate mastery in their roles
Then the FDA made a move, and suddenly everyone who had a standing order is in full panic mode